Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 11/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 11/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 11/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258584 | 0.75 | ADORA2A (0.59) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27774795 | 0.74 | HSP90AA1 (0.52) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL16487121 | 0.73 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5146335 | 0.72 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27774840 | 0.72 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27469939 | 0.70 | CYP1A2 (0.41) | EGFRALDH1A1 | |
| SCHEMBL134910 | 0.70 | EGFR (0.61) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL9373702 | 0.70 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL6699970 | 0.69 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| 9-Benzyl-9H-Adenine SCHEMBL104932 | 0.69 | ADORA2A (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | PI4KA 2175/4885PI4K2B 3080/4885PI4K2A 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.